Report on the preliminary data from Immunopheresis study by Immunicom.
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Report on the preliminary data from Immunopheresis study by Immunicom.

Pharma Tech Outlook | Thursday, December 30, 2021

The result of clinical-stage biotech pioneering subtractive therapies for advanced cancers was presented by Immunicom.

FREMONT, CA: The promising preliminary data from a clinical trial investigating Immunopheresis therapy for resistant melanoma and other solid cancers was presented by Immunicom - a clinical-stage biotech pioneering subtractive therapies for advanced cancers - at the Society for Immunotherapy of Cancer (SITC) 2021's 36th annual meeting. This clinical trial uses Immunicom's proprietary, subtractive LW-02 column to selectively remove immunosuppressive soluble tumor necrosis factor receptors (sTNF-Rs) via apheresis which was conducted at Sheba Medical Center. This therapy is designed to free the cytokine TNF-alpha by depleting TNF receptors from plasma and thereby unleashing its potent anti-cancer effects.

The evaluation of the safety and the clinical effectiveness of Immunopheresis as a monotherapy, and in combination with Bristol Myers Squibb's anti-PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), in heavily pretreated patients is been done in the basket oncology clinical which is conducted under the direction of Dr. Ronnie Shapira, MD, and Prof. Gal Market, MD Ph.D. Preliminary data were presented from Part A that is Immunopheresis therapy alone from six patients, who failed multiple prior lines of standard chemo and immunotherapies, of whom three were with melanoma and three with triple-negative breast cancer (TNBC). Of these six heavily pretreated patients, three were withdrawn due to clinical progression and three completed the 12-week study regime.

After a year, two patients are still alive with a median overall survival of 26.6 weeks. Immunopheresis therapy did not report any treatment-related serious adverse events and was well-tolerated in these late-stage patients. In order to significantly reduce the levels of sTNF-Rs in plasma, this therapy was demonstrated. The evidence of up regulation of protein biomarkers and cell populations that are associated with the improved activity of the immune system was seen in immune profiling of blood and tumor specimens.

 

Weekly Brief

Read Also